CLAIMS

1. Use of a pharmaceutical combination of Trametinib and a kinase inhibitor in the manufacture of a medicament for the treatment of pancreatic cancer, wherein the kinase inhibitor is at least one selected from the group consisting of AD80, Adavosertib, Alisertib, BI-831266 and Y-27632.

2. The use of a pharmaceutical combination according to claim 1, wherein the kinase inhibitor is BI-831266.

3. Use of a kinase inhibitor in combination with Trametinib in the manufacture of a medicament for the treatment of pancreatic cancer, wherein the kinase inhibitor is at least one selected from the group consisting of AD80, Adavosertib, Alisertib, BI-831266 and Y-27632.

4. The use of a kinase inhibitor according to claim 3, wherein the kinase inhibitor is BI-831266.

5. Use of Trametinib in combination with a kinase inhibitor in the manufacture of a medicament for the treatment of pancreatic cancer, wherein the kinase inhibitor is at least one selected from the group consisting of AD80, Adavosertib, Alisertib, BI-831266 and Y-27632.

6. The use of Trametinib according to claim 5, wherein the inhibitor is BI-831266.

7. The use of a pharmaceutical combination according to claim 1 or 2, the use of a kinase inhibitor in combination with Trametinib according to claim 3 or 4, or the use of Trametinib in combination with a kinase inhibitor according to claim 5 or 6, wherein the pharmaceutical combination is in a form of formulation containing two or more types of kinase inhibitors together or in a combination of forms of individual formulations of kinase inhibitors.

8. The use of claim 7, wherein the medicament is to be administered together or individually, simultaneously or sequentially to a subject in need of treatment.